Announced Date: 2025-06-02 (June 2, 2024)
Asset Name: HS-20094
Licensor: Hansoh (Hansoh Pharmaceuticals Group, China)
Licensee (Buyer): Regeneron (Regeneron Pharmaceuticals, Inc., USA)
.
Asset Modality: Small Molecule
Asset Target: dual GLP-1/GIP receptor agonist （weekly subcutaneous injection）
Current Stage: Phase III, China
Scope of Authority:
Hansoh Pharma has granted Regeneron an exclusive clinical development and commercial rights outside of the Chinese Mainland, Hong Kong and Macau for HS-20094.
Deal Detail:
Upfront payment of $80 million,
Milestone payments up to $1.93 billion,
Total up to $2.01 billion.
Future potential royalties for global net sales outside of the designated territories would be in the low double digits.
.
Link:
Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
